Published in Dig Dis Sci on August 24, 2012
HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer (2014) 0.86
Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer (2015) 0.86
Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol (2013) 0.86
Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PLoS One (2013) 0.84
HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach. Dis Markers (2015) 0.84
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One (2013) 0.83
Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget (2015) 0.80
HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. Gastric Cancer (2014) 0.80
Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci (2016) 0.79
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol (2009) 5.66
Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology (2008) 5.31
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol (2008) 4.63
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science (1986) 3.74
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol (2003) 3.14
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med (2009) 2.97
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer (2005) 2.02
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol (2010) 1.93
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep (2006) 1.91
Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol (2010) 1.65
Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol (2008) 1.62
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol (2006) 1.56
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat (2005) 1.52
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
Targeted HER2 treatment in advanced gastric cancer. Oncology (2010) 1.39
Her-2/neu and breast cancer. Diagn Mol Pathol (2001) 1.38
Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res (1990) 1.38
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer (2011) 1.34
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol (2008) 1.31
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology (2011) 1.29
Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer (1991) 1.25
Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys (2012) 1.25
Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol (2002) 1.18
HER 2/neu protein expression in colorectal cancer. BMC Cancer (2006) 1.18
Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol (2011) 1.17
Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology (2011) 1.16
HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol (2004) 1.15
HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol (1992) 1.11
Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci (2010) 1.07
Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn J Clin Oncol (2007) 0.98
Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol (2005) 0.98
HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer (2010) 0.92
[HER2 and gastric cancer. Recommendations for clinical practice in 2011]. Ann Pathol (2011) 0.81
TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology (2010) 0.79
Composite carcinoid-adenocarcinoma of the stomach associated with multiple gastric carcinoids and nonantral gastric atrophy. Cancer (1989) 1.03
Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res (1998) 1.02
Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res (2000) 1.01
Gender differences in wall shear-mediated brachial artery vasoconstriction and vasodilation. J Am Coll Cardiol (2001) 1.00
Short- and long-term reproducibility of time and frequency domain heart rate variability measurements in normal subjects. Cardiovasc Res (1996) 0.99
Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: effect of N-acetylcysteine and interferon-alpha. Toxicol Appl Pharmacol (2001) 0.98
Primary Hodgkin's disease of the stomach. A case report. Tumori (1992) 0.97
COACH syndrome: report of two brothers with congenital hepatic fibrosis, cerebellar vermis hypoplasia, oligophrenia, ataxia, and mental retardation. Am J Med Genet (1996) 0.96
Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res (1997) 0.95
High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation. J Am Coll Cardiol (1997) 0.92
New phenotypic aspects in a family with Lynch syndrome II. Cancer (1987) 0.92
Histological identification of Helicobacter pylori in early and advanced gastric cancer. J Clin Gastroenterol (1990) 0.91
Smooth muscle role on pulmonary arterial function during acute pulmonary hypertension in sheep. Acta Physiol Scand (2004) 0.91
Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res (2000) 0.87
Inconsistency of the slope and the volume intercept of the end-systolic pressure-volume relationship as individual indexes of inotropic state in conscious dogs: presentation of an index combining both variables. Circulation (1987) 0.86
Different human papillomavirus genotypes in ano-genital lesions. Anticancer Res (2000) 0.85
Duodenogastric reflux, histology and cell proliferation of the gastric mucosa before and six months after cholecystectomy. Acta Gastroenterol Belg (1995) 0.84
Helicobacter pylori in animals affecting the human habitat through the food chain. Anticancer Res (2000) 0.84
Helicobacter pylori strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment Pharmacol Ther (2003) 0.83
Increased reversal and oscillatory shear stress cause smooth muscle contraction-dependent changes in sheep aortic dynamics: role in aortic balloon pump circulatory support. Acta Physiol (Oxf) (2007) 0.83
A prospective study on duodenogastric reflux and on histological changes in gastric mucosa after cholecystectomy. Gastroenterol Clin Biol (1992) 0.83
Sex steroid hormone receptors and human gallbladder motility in vitro. Digestion (1990) 0.83
Ulcerative colitis in remission: it is possible to predict the risk of relapse? Digestion (1989) 0.82
Depressed level of natural killer cells in cancer family syndrome. Cancer Immunol Immunother (1989) 0.81
Association between granulomatous colitis in French Bulldogs and invasive Escherichia coli and response to fluoroquinolone antimicrobials. J Vet Intern Med (2012) 0.81
Polyamine levels and ODC activity in intestinal-type and diffuse-type gastric carcinoma. Dig Dis Sci (1997) 0.80
Holter-guided identification of premature ventricular contractions susceptible to suppression by beta-blockers. Am Heart J (1996) 0.80
Cancer family syndrome: cytogenetic investigations, in vitro tetraploidy, and biomarker studies in a large family. J Med Genet (1990) 0.79
Immunohistochemical reactivity of anti-melanoma monoclonal antibody 225.28S in human breast cancer biopsies. Anticancer Res (2001) 0.79
Colonic smooth muscle responses in patients with diverticular disease of the colon: effect of the NK2 receptor antagonist SR48968. Dig Liver Dis (2004) 0.79
Detection of Helicobacter pylori cagA gene by polymerase chain reaction in faecal samples. Eur J Gastroenterol Hepatol (1999) 0.79
Complete response to chemotherapy in intra-abdominal desmoplastic small round cell carcinoma. A case report. Tumori (1998) 0.79
Clinical and angiographic outcome after Palmaz-Schatz stent implantation guided by intravascular ultrasound. J Invasive Cardiol (1995) 0.79
Duodenogastric reflux of bile acids, gastrin and parietal cells, and gastric acid secretion before and 6 months after cholecystectomy. Am J Surg (1990) 0.78
Oestrogen receptors and microsatellite instability in colorectal carcinoma patients. Cancer Lett (2001) 0.78
Carcinoma and synchronous hyperplastic polyps of the large bowel. Pathologica (1994) 0.78
Subclinical atherosclerosis modeling: Integration of coronary artery calcium score to Framingham equation. Conf Proc IEEE Eng Med Biol Soc (2009) 0.78
Role of prognostic factors in the therapeutic strategy of primary gastric non Hodgkin's lymphomas. Clin Ter (1998) 0.78
Programmed cell death in colorectal carcinogenesis. Anticancer Res (2000) 0.77
Is the use of t-PA as compared with streptokinase cost effective? N Engl J Med (1995) 0.77
Duodenogastric reflux and gastric histology after cholecystectomy with or without sphincteroplasty. Br J Surg (1990) 0.77
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies. Med Chem (2005) 0.77
Carotid wall inertial index increase is related to intima-media thickening in hypertensive patients. J Hypertens (1999) 0.77
P-170 glycoprotein expression in gastric and colorectal carcinomas and normal mucosa. An immunocytochemical study. In Vivo (1995) 0.76
[Granulomatous hepatitis in a hospital population in southern Italy]. Pathologica (1994) 0.76
Tauroursodeoxycholic acid reduces damaging effects of taurodeoxycholic acid on fundus gastric mucosa. Arch Physiol Biochem (2002) 0.76
Demonstration of a direct stimulatory effect of bile salts on rat colonic epithelial cell proliferation. Scand J Gastroenterol (2002) 0.76
Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder. Dig Dis Sci (2001) 0.76
The immunohistochemical expression of cathepsin D in colorectal cancer. Anticancer Res (1996) 0.76
Non-symmetrical double-logistic analysis of 24 hour arterial stiffness profile in normotensive and hypertensive subjects. Conf Proc IEEE Eng Med Biol Soc (2008) 0.76
Species differences in hepatic bile acid uptake: comparative evaluation of taurocholate and tauroursodeoxycholate extraction in rat and rabbit. Comp Biochem Physiol A Physiol (1996) 0.76
Main characteristics of hepatocellular carcinoma and cirrhosis and therapeutic approaches. Curr Pharm Des (2002) 0.76
[DNA content in colorectal carcinomas: application of image analysis to archival material]. Pathologica (1994) 0.75
Correlation of cineangiographic and pathology findings in coronary artery disease. Acta Cardiol (1986) 0.75
[Paget's disease of the vulva. Review and case report]. Minerva Ginecol (1982) 0.75
[Vascular dysfunction in hypertension evaluated by nonivasive assessment of arterial impedance]. Medicina (B Aires) (1998) 0.75
Arterial pressure and diameter waveforms analysis by means of wavelet transform: application to artery de-endothelization. Conf Proc IEEE Eng Med Biol Soc (2010) 0.75
Multiple synchronous colorectal carcinomas: a ploidy study by image analysis. Anticancer Res (1998) 0.75
[Early gastric cancer: determination of estrogen receptors using the immunohistochemical ABC method in 20 cases]. Pathologica (1988) 0.75
[Adenoma-carcinoma sequence in the right colon]. Minerva Dietol Gastroenterol (1989) 0.75
[Vertebral fracture caused by electric cardioversion]. G Ital Cardiol (1987) 0.75
Do arterial effects of antihypertensive drugs depend on subject's serum cholesterol? J Cardiovasc Pharmacol (2001) 0.75
[Intragastric pH determination as a screening test in the diagnosis of chronic atrophic gastritis]. Minerva Med (1989) 0.75
Immunohistochemical detection of p53 protein in anogenital lesions and its relationship with HPV status. Anticancer Res (1999) 0.75
[Systematic intraoperative hepatic needle biopsy in surgery of benign pathology of the stomach, duodenum and bile ducts]. Chir Patol Sper (1982) 0.75
[Clinical aspects and morphology of endometriosis. Study of 38 cases]. Minerva Ginecol (1988) 0.75
[Cefadroxil in stomatology]. Minerva Stomatol (1984) 0.75
Effect of somatostatin on human gallbladder motility: an in vitro study. Neurogastroenterol Motil (1999) 0.75
[Cardiologic aspects of Kawasaki's disease]. Pediatr Med Chir (1988) 0.75
[Chronic gastritis. Guidelines and minimum diagnostic criteria. Italian Digestive System Pathologists Group]. Pathologica (1997) 0.75
[Cariostatic effect of Fluocaril; controlled clinical research]. Minerva Stomatol (1981) 0.75
Immunohistochemical expression of ps2 and cathepsin-d in breast-cancer - relationship with er, pgr immunostainings and clinicopathological aspects. Oncol Rep (1994) 0.75
Localization of p53 protein and human papillomavirus in laryngeal squamous lesions. Anticancer Res (1998) 0.75
Can peanut agglutinin distinguish between pseudo and true invasion in colonic adenomas? Eur J Histochem (1993) 0.75
Flow behavior and applicability of models for different hemodynamic states. Conf Proc IEEE Eng Med Biol Soc (2010) 0.75
Gallbladder motility in vitro in men with gallstones following Billroth II gastric resection. Neurogastroenterol Motil (1996) 0.75
Nine novel APC mutations in Italian FAP patients. Hum Mutat (2001) 0.75
Aortic pulsatile pressure and diameter response to intravenous perfusions of angiotensin, norepinephrine, and epinephrine in conscious dogs. J Cardiovasc Pharmacol (1988) 0.75
[A case of true diverticulum of the cecum]. Ann Osp Maria Vittoria Torino (1981) 0.75
[Static cytometry in the study of ploidy patterns and cellular kinetics in carcinoma of the breast]. Pathologica (1993) 0.75
Dynamics of cryopreserved human carotid arteries. Conf Proc IEEE Eng Med Biol Soc (2004) 0.75
In vitro gallbladder motility in patients with radiolucent and radiopaque stones. Digestion (1991) 0.75
[Kawasaki disease: recent findings in etiology, pathogenesis and therapy]. Pediatr Med Chir (1989) 0.75
[Immunoperoxidases in the study of hormone receptors in colorectal cancer]. Pathologica (1988) 0.75
[Vascular access for haemodyalisis. Comparative analysis of the mechanical behaviour of native vessels and prosthesis]. Nefrologia (2006) 0.75
[Histologic findings in laser radiation of myocardial pericrater in dogs]. Arch Inst Cardiol Mex (1990) 0.75